Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosis
- 1 January 2025
- journal article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 328 (1) , G51-G71
Abstract
The CDAA-HFD mouse model is widely used in preclinical MASH research, but validation of the model is lacking. This study presents the longitudinal characterization of disease progression. Furthermore, late-stage clinical compounds and dietary intervention (chow reversal) display distinct hepatoprotective effects in the model. Collectively, the study provides critical information guiding the use of the CDAA-HFD mouse model in preclinical drug discovery for MASH and fibrosis.Keywords
This publication has 80 references indexed in Scilit:
- Nonobese mice with nonalcoholic steatohepatitis fed on a choline‐deficient, l‐amino acid‐defined, high‐fat diet exhibit alterations in signaling pathwaysFEBS Open Bio, 2021
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASHHepatology, 2020
- The Role of Innate Immune Cells in Nonalcoholic SteatohepatitisHepatology, 2019
- Animal Models of Type 2 Diabetes, Obesity and Nonalcoholic Steatohepatitis – Clinical Translatability and Applicability in Preclinical Drug Development2019
- Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic SteatohepatitisDigestive Diseases and Sciences, 2018
- Mouse Models of Nonalcoholic SteatohepatitisHepatology, 2018
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐upHepatology, 2014
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitisHepatology, 2013
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985